Deals Of The Week: Novartis/Enanta, Ligand/Retrophin, Auxilium/Actelion, Amgen/Dako
A prosaic week in biopharma deal-making leads DOTW to ponder a brain-computer interface specialist’s efforts to apply its technology to patients with severe communication limitations.
You may also be interested in...
The Phase I-ready compound joins alisporivir, a cyclophilin inhibitor licensed from Debiopharm in 2010, in Novartis’ rather slight portfolio of HCV candidates.
The manufacturer expected Xiaflex to take off as a non-invasive, more effective alternative to hand surgery, but the market has been slow to convert, prompting Auxilium to shift around its commercial organization.
Though clinical proof-of-concept has long been the goal of fledgling biotechs hoping to land a deep-pocketed partner or acquirer, data suggest reaching this inflection point may no longer provide an optimal risk-reward balance. Biotechs would be wise to partner earlier.